This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Discussing the Pneumococcal vaccine market and where a new vaccine could potentially fit in
Ticker(s): PFE, PCVX, GSK, MRK, Affinivax, ALPMYWho's the expert?
Institution: NYU Langone
- Adjunct Instructor, Department of Medicine at NYU Grossman School of Medicine.
- Internal Medicine physician practicing at Sunset Park Family Health Center at NYU Langone with ambulatory care expertise treating adult patients (18-100).
- Regularly prescribes prevnar13, Synflorix, and pneumovax 23 (~500-600 patients).
Interview GoalDiscussing the Pneumococcal vaccine market including Prevnar 13/20, Synflorix, and Pneumovax23 and where a new vaccine could potentially fit in.This conversation will also discuss VAX-24 from Vaxcyte, and ASP3772, a Novel 24-Valent Pneumococcal Vaccine for use in older adults currently in development by Affinivax/Astellas.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
